Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD

Alexander J. Kula

doi:10.1007/s00467-022-05456-x

Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD

Alexander J. Kula^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as glucose-lowering agents. These medications function by inhibiting glucose and sodium reabsorption in the S1 segment of the proximal tubule. Early clinical trials in adults with type 2 diabetes mellitus (T2DM) suggested a significant improvement in kidney and cardiovascular outcomes with SGLT2i therapy. Since then, SGLT2is have become a mainstay treatment for adult patients with CKD. A growing body of research has explored deploying these medications in new clinical contexts and investigated the mechanisms underlying their physiologic effects. However, patients under the age of 18 years have been largely excluded from all major trials of SGLT2i. This review aims to summarize the available clinical evidence, physiology, and mechanisms relating to SGLT2is to inform discussions about their implementation in pediatrics.

Original language	English (US)
Pages (from-to)	2267-2276
Number of pages	10
Journal	Pediatric Nephrology
Volume	37
Issue number	10
DOIs	https://doi.org/10.1007/s00467-022-05456-x
State	Published - Oct 2022
Externally published	Yes

Keywords

Mechanisms
Pediatric CKD
SGLT2 inhibitor

ASJC Scopus subject areas

Nephrology
Pediatrics, Perinatology, and Child Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00467-022-05456-x

Cite this

@article{f2d2994087284a94803af2df8edeb274,

title = "Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD",

abstract = "Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as glucose-lowering agents. These medications function by inhibiting glucose and sodium reabsorption in the S1 segment of the proximal tubule. Early clinical trials in adults with type 2 diabetes mellitus (T2DM) suggested a significant improvement in kidney and cardiovascular outcomes with SGLT2i therapy. Since then, SGLT2is have become a mainstay treatment for adult patients with CKD. A growing body of research has explored deploying these medications in new clinical contexts and investigated the mechanisms underlying their physiologic effects. However, patients under the age of 18 years have been largely excluded from all major trials of SGLT2i. This review aims to summarize the available clinical evidence, physiology, and mechanisms relating to SGLT2is to inform discussions about their implementation in pediatrics.",

keywords = "Mechanisms, Pediatric CKD, SGLT2 inhibitor",

author = "Kula, {Alexander J.}",

note = "Funding Information: In part, this work was supported by Seattle Children{\textquoteright}s Hospital/University of Washington NIH T32DK997662. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to International Pediatric Nephrology Association.",

year = "2022",

month = oct,

doi = "10.1007/s00467-022-05456-x",

language = "English (US)",

volume = "37",

pages = "2267--2276",

journal = "Pediatric Nephrology",

issn = "0931-041X",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD

AU - Kula, Alexander J.

N1 - Funding Information: In part, this work was supported by Seattle Children’s Hospital/University of Washington NIH T32DK997662. Publisher Copyright: © 2022, The Author(s), under exclusive licence to International Pediatric Nephrology Association.

PY - 2022/10

Y1 - 2022/10

N2 - Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as glucose-lowering agents. These medications function by inhibiting glucose and sodium reabsorption in the S1 segment of the proximal tubule. Early clinical trials in adults with type 2 diabetes mellitus (T2DM) suggested a significant improvement in kidney and cardiovascular outcomes with SGLT2i therapy. Since then, SGLT2is have become a mainstay treatment for adult patients with CKD. A growing body of research has explored deploying these medications in new clinical contexts and investigated the mechanisms underlying their physiologic effects. However, patients under the age of 18 years have been largely excluded from all major trials of SGLT2i. This review aims to summarize the available clinical evidence, physiology, and mechanisms relating to SGLT2is to inform discussions about their implementation in pediatrics.

AB - Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as glucose-lowering agents. These medications function by inhibiting glucose and sodium reabsorption in the S1 segment of the proximal tubule. Early clinical trials in adults with type 2 diabetes mellitus (T2DM) suggested a significant improvement in kidney and cardiovascular outcomes with SGLT2i therapy. Since then, SGLT2is have become a mainstay treatment for adult patients with CKD. A growing body of research has explored deploying these medications in new clinical contexts and investigated the mechanisms underlying their physiologic effects. However, patients under the age of 18 years have been largely excluded from all major trials of SGLT2i. This review aims to summarize the available clinical evidence, physiology, and mechanisms relating to SGLT2is to inform discussions about their implementation in pediatrics.

KW - Mechanisms

KW - Pediatric CKD

KW - SGLT2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85123918328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123918328&partnerID=8YFLogxK

U2 - 10.1007/s00467-022-05456-x

DO - 10.1007/s00467-022-05456-x

M3 - Review article

C2 - 35088160

AN - SCOPUS:85123918328

SN - 0931-041X

VL - 37

SP - 2267

EP - 2276

JO - Pediatric Nephrology

JF - Pediatric Nephrology

IS - 10

ER -

Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this